Araştırma Makalesi

Determination of synergic antioxidant interactions of Ellagic acid and chemotherapy drug (Docetaxel and Mitoxantron) combinations

Cilt: 14 Sayı: 3 15 Eylül 2024
PDF İndir
TR EN

Determination of synergic antioxidant interactions of Ellagic acid and chemotherapy drug (Docetaxel and Mitoxantron) combinations

Abstract

Chemotherapy drugs are commonly used in cancer treatment, despite their numerous negative side effects. Today, there are studies to reduce the side effects of these drugs and to increase their benefits by combining them with natural substances. Our study investigated the antioxidant and antiradical activities of Ellagic acid (EA), a natural substance, DOC and MIX, commonly used chemotherapeutics, as well as their combinations (EA+DOC, EA+MIX). For this purpose, the methods of DPPH• and ABTS•+ scavenging activity, Fe3+-Fe2+ and Cu2+-Cu1+ reduction capacity were used. After the study, the interactions were analysed with the combination index using Compusyn software. Concentrations with maximum synergy in combinations have been identified. For this purpose, firstly, the combination concentrations used in the antioxidant activity methods and the absorbance values were entered into the Compusyn programme. When DPPH• and ABTS•+ scavenging activity results were entered into the programme, more effective synergistic effect was observed for EA+DOC at lower concentrations (7:7µg/mL), (0.125:1µg/mL) respectively. For EA+MIX, no synergistic effect was observed with the application of DPPH scavenging activity results to the programme, while for ABTS•+ scavenging activity, more effective synergistic effect was observed at higher concentrations within the applied doses (0.750:6µg/ml). When Fe3+-Fe2+ and Cu2+-Cu1+ reduction results were applied to the programme; synergistic effect was observed at higher concentrations (17:17µg/mL) for both EA+DOC and EA+MIX and even strong synergistic effect was observed in many of them. The obtained results provide guidance for the use of these combinations in further studies, such as anticancer and enzyme studies.

Keywords

Antioxidant , Chemotherapy , Compusyn , Drug , Synergistic

Kaynakça

  1. Anantharaju, P. G., Gowda, P. C., Vimalambike, M. G. & Madhunapantula, S. V. (2016). An overview on the role of dietary phenolics for the treatment of cancers. Nutrition Journal, 15(99), 1–16. https://doi.org/10.1186/s12937-016-0217-2
  2. Apak, R., Güçlü, K., Özyürek, M., Karademir, S. E. & Erça, E. (2006). The cupric ion reducing antioxidant capacity and polyphenolic content of some herbal teas. International Journal of Food Sciences and Nutrition, 57(5-6), 292–304. https://doi.org/10.1080/09637480600798132
  3. Ayvat, İ. (2019). Ayaktan kemoterapi alan kanser hastalarının karşılanmamış destekleyici bakım gereksinimlerinin yaş bağlamında incelenmesi. [Yüksek Lisans Tezi, Hacettepe Üniversitesi, Sağlık Bilimleri Enstitüsü].
  4. Aziz, A., Sarwar, S., Akter, T., Uddin, S., Xun, S., Zhu, Y., Islam, M. S. & Hongjie, Z. (2021). Polyphenolic molecules targeting STAT3 pathway for the treatment of cancer. Life Sciences, 268, 118999. https://doi.org/10.1016/j.lfs.2020.118999
  5. Blois, M. S. (1958). Antioxidant determinations by the use of a stable free radical. Nature, 26, 1199-1200. https://doi.org/10.1038/1811199a0
  6. Buczkowski, A., Tokarz, P., Stepniak, A., Lewkowski, J., Rodacka, A. & Palecz, B. (2019). Spectroscopic and calorimetric studies of interactions between Mitoxantrone and cucurbituril Q7 in aqueous solutions. Journal of Molecular Liquids, 290, 111190. https://doi.org/10.1016/j.molliq.2019.111190
  7. Chai, H., Wu, J., Liu, J., Liu, T., Ren, Q. & Zheng, X. (2021). δ-tocopherol enhances Docetaxel-ınduced growth ınhibition and apoptosis in ovarian cancer SKOV3 cells. Natural Product Communications, 16(3), 1–8. https://dx.doi.org/10.1177/1934578X211002298
  8. Chou, T. C. (2006). Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews, 58(3), 621–681. https://doi.org/10.1124/pr.58.3.10
  9. Chou, T. C. (2010). Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Research, 70(2), 440–446. https://doi.org/10.1158/0008-5472.CAN-09-1947
  10. Durante, S., Dunet, V., Gorostidi, F., Mitsakis, P., Schaefer, N., Delage, J. & Prior, J. O. (2020). Head and neck tumors angiogenesis imaging with 68Ga-NODAGA-RGD in comparison to 18F-FDG PET/CT: A pilot study. EJNMMI Research, 10(1), 1–11. 1 https://doi.org/0.1186/s13550-020-00638-w.

Kaynak Göster

APA
Zehiroğlu, C., & Ö. Sarıkaya, S. B. (2024). Determination of synergic antioxidant interactions of Ellagic acid and chemotherapy drug (Docetaxel and Mitoxantron) combinations. Gümüşhane Üniversitesi Fen Bilimleri Dergisi, 14(3), 735-750. https://doi.org/10.17714/gumusfenbil.1430653